{"bill": {"#text": "\n\t", "form": {"current-chamber": {"#tail": "\n\t\t", "#text": "IN THE HOUSE OF REPRESENTATIVES"}, "#text": "\n\t\t", "congress": {"#tail": "\n\t\t", "#text": "113th CONGRESS"}, "#tail": "\n\t", "legis-num": {"#tail": "\n\t\t", "#text": "H. R. 2315"}, "official-title": {"#tail": "\n\t", "#text": "To clarify the orphan drug exception to the annual fee on\n\t\t  branded prescription pharmaceutical manufacturers and\n\t\t  importers."}, "session": {"#tail": "\n\t\t", "#text": "1st Session"}, "distribution-code": {"#tail": "\n\t\t", "@display": "yes", "#text": "I"}, "action": {"action-date": {"#tail": "\n\t\t\t", "@date": "20130611", "#text": "June 11, 2013"}, "#tail": "\n\t\t", "action-desc": {"#tail": "\n\t\t", "#text": "\n        ", "committee-name": [{"#tail": ", and in\n\t\t\t addition to the Committee on ", "@committee-id": "HIF00", "#text": "Committee on Energy and Commerce"}, {"#tail": ", for a period to be subsequently determined by the\n\t\t\t Speaker, in each case for consideration of such provisions as fall within the\n\t\t\t jurisdiction of the committee concerned", "@committee-id": "HWM00", "#text": "Ways and\n\t\t\t Means"}], "sponsor": {"#tail": " (for\n\t\t\t himself and ", "#text": "Mr. Gerlach", "@name-id": "G000549"}, "cosponsor": {"#tail": ") introduced the\n\t\t\t following bill; which was referred to the ", "#text": "Mr. Neal", "@name-id": "N000015"}}, "#text": "\n\t\t\t"}, "legis-type": {"#tail": "\n\t\t", "#text": "A BILL"}}, "@bill-stage": "Introduced-in-House", "@bill-type": "olc", "@dms-id": "H89CFEC2CE5F143A28E7B8A826B274450", "@public-private": "public", "legis-body": {"#tail": "\n", "@style": "OLC", "section": [{"@section-type": "section-one", "#tail": "\n    ", "text": {"#tail": "\n\t\t", "quote": {"short-title": {"#tail": "\n        ", "#text": "Preserving Access to Orphan Drugs Act\n\t\t\t of 2013"}, "#tail": ".", "#text": "\n          "}, "#text": "This Act may be cited as the\n\t\t\t ", "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "1."}, "header": {"#tail": "\n      ", "#text": "Short title"}, "#text": "\n      ", "@id": "H5B8AAA03A71E42A486FF44FC4CD05D7E"}, {"@section-type": "subsequent-section", "#tail": "\n  ", "enum": {"#tail": "\n      ", "#text": "2."}, "header": {"#tail": "\n\t\t\t", "#text": "Clarification of\n\t\t\t orphan drug exception to annual fee on branded prescription pharmaceutical\n\t\t\t manufacturers and importers"}, "subsection": [{"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "#text": "\n          ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended to read as follows:", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " (", "@entity-type": "act", "#text": "Paragraph (3) of\n\t\t\t section 9008(e) of the Patient Protection and Affordable Care Act", "@value": "Patient Protection and Affordable Care Act/s:9008/ss:e/p:3"}, {"#tail": ")", "@entity-type": "public-law", "#text": "Public Law\n\t\t\t 111\u2013148", "@value": "public-law/111/148"}], "@entity-type": "law-citation", "#text": "\n            "}, "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n        ", "#text": "(a)"}, "header": {"#tail": "\n        ", "#text": "In\n\t\t\t general"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n        ", "#text": "."}, "#tail": "\n\t\t\t", "paragraph": {"#tail": "\n          ", "subparagraph": [{"#tail": "\n            ", "clause": [{"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "; or", "@entity-type": "act", "#text": "section 45C of the\n\t\t\t\tInternal Revenue Code of 1986", "@value": "Internal Revenue Code of 1986/s:45C"}, "#text": "with respect to\n\t\t\t\twhich a credit was allowed for any taxable year under "}, "enum": {"#tail": "\n                ", "#text": "(i)"}, "#text": "\n                ", "@id": "H929C01632E0D4F91BD47C62A7BDE0BE7", "@commented": "no"}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " for marketing solely for one or\n\t\t\t\tmore rare diseases or conditions.", "@entity-type": "federal-body", "#text": "Food and Drug Administration", "@entity-id": "7524"}, "#text": "which is approved\n\t\t\t\tor licensed by the "}, "enum": {"#tail": "\n                ", "#text": "(ii)"}, "#text": "\n                ", "@id": "H39E06524DC8A432AA49A9D8F5A5D79BC", "@commented": "no"}], "enum": {"#tail": "\n              ", "#text": "(A)"}, "header": {"#tail": "\n              ", "#text": "In\n\t\t\t\tgeneral"}, "text": {"#tail": "\n\t\t\t\t\t\t\t", "term": {"#tail": " shall not include sales of any\n\t\t\t\tdrug or biological product\u2014", "#text": "branded prescription drug sales"}, "#text": "The term\n\t\t\t\t", "@display-inline": "yes-display-inline"}, "#text": "\n              ", "@id": "H7B5ADACBD2B44DC3ADCAF6EEA5638DA5", "@commented": "no"}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall not apply with respect to any drug or biological product after the\n\t\t\t\tdate on which the drug or biological product is approved or licensed by the\n\t\t\t\t", "@entity-type": "act", "#text": "Subparagraph\n\t\t\t\t(A)", "@value": "Patient Protection and Affordable Care Act/s:90008/ss:e/p:3/sp:A", "@proposed": "true"}, {"#tail": " for marketing for any indication other than the\n\t\t\t\ttreatment of a rare disease or condition.", "@entity-type": "federal-body", "#text": "Food and Drug Administration", "@entity-id": "7524"}], "#text": "\n                "}, "enum": {"#tail": "\n              ", "#text": "(B)"}, "header": {"#tail": "\n              ", "#text": "Limitation"}, "#text": "\n              ", "@id": "H846159FA93FB4FDC9FCBFEB75086D30B", "@commented": "no"}, {"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", except that in the case of any drug or\n\t\t\t\tbiological product that has not been designated under ", "@entity-type": "act", "#text": "section 45C(d)(1) of the\n\t\t\t\tInternal Revenue Code of 1986", "@value": "Internal Revenue Code of 1986/s:45C/ss:d/p:1"}, {"#tail": " for a particular indication,\n\t\t\t\tdeterminations under such ", "@entity-type": "act", "#text": "section 526 of the\n\t\t\t\tFederal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:526"}, {"#tail": " shall be made on the basis of the\n\t\t\t\tfacts and circumstances as of the date such drug or biological product is\n\t\t\t\tapproved or licensed by the ", "@entity-type": "act", "#text": "section 45C(d)(1)", "@value": "Internal Revenue Code of 1986/s:45C/ss:d/p:1"}, {"#tail": " for marketing for the\n\t\t\t\ttreatment of such disease or\n\t\t\t\tcondition.", "@entity-type": "federal-body", "#text": "Food and Drug Administration", "@entity-id": "7524"}], "term": {"#tail": " has the meaning given such term under ", "#text": "rare disease or\n\t\t\t\tcondition"}, "#text": "In this paragraph, the term "}, "enum": {"#tail": "\n              ", "#text": "(C)"}, "header": {"#tail": "\n              ", "#text": "Rare disease or\n\t\t\t\tcondition"}, "#text": "\n              ", "@id": "H37609241177F42CF801F617428392892", "@commented": "no"}], "enum": {"#tail": "\n            ", "#text": "(3)"}, "header": {"#tail": "\n\t\t\t\t\t\t", "#text": "Exclusion of\n\t\t\t\torphan drug sales"}, "#text": "\n            ", "@id": "H289A0D32ED1A4AED9A465B11C61B7462", "@commented": "no"}, "@display-inline": "no-display-inline", "#text": "\n\t\t\t\t\t", "@id": "H757315418F1C49D5AD40EF3C5B1C03F3"}, "#text": "\n        ", "@id": "HDC3B04CE008548C4878F0A6C629126BF", "@commented": "no"}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t\t", "#text": "The amendment made by this section shall take effect as if\n\t\t\t included in ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": ".", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n\t\t\t (", "@entity-type": "act", "#text": "section 9008 of the Patient Protection and Affordable Care Act", "@value": "Patient Protection and Affordable Care Act/s:9008"}, "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n            ", "@entity-type": "public-law", "#text": "Public Law 111\u2013148", "@value": "public-law/111/148"}, "@parsable-cite": "pl/111/148", "#text": "\n              ", "@legal-doc": "public-law"}}}, "enum": {"#tail": "\n        ", "#text": "(b)"}, "header": {"#tail": "\n        ", "#text": "Effective\n\t\t\t date"}, "#text": "\n        ", "@id": "HC5F31F1C3FD540099EF28B8C76626431"}], "#text": "\n      ", "@id": "H3DDDDE1133A544F1ABF5DA9089ABEE02"}], "#text": "\n\t\t", "@id": "H9C95222EF6B746FD8CB6E7E56B532D7C"}, "metadata": {"#tail": "\n", "dublinCore": {"{http://purl.org/dc/elements/1.1/}date": {"#tail": "\n", "#text": "2013-06-11"}, "{http://purl.org/dc/elements/1.1/}format": {"#tail": "\n", "#text": "text/xml"}, "{http://purl.org/dc/elements/1.1/}language": {"#tail": "\n", "#text": "EN"}, "#tail": "\n", "{http://purl.org/dc/elements/1.1/}title": {"#tail": "\n", "#text": "113 HR 2315 IH: Preserving Access to Orphan Drugs Act of 2013"}, "{http://purl.org/dc/elements/1.1/}rights": {"#tail": "\n", "#text": "Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain."}, "{http://purl.org/dc/elements/1.1/}publisher": {"#tail": "\n", "#text": "U.S. House of Representatives"}, "#text": "\n"}, "#text": "\n"}}}